What is the current market size?

The Mycoplasma Pneumoniae Antigen Detection Kit market size was valued at USD 1.2 billion in 2023, driven by rising respiratory infection cases and diagnostic advancements.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2026 to 2033, fueled by increased healthcare investments and technological innovations.

What drives market expansion?

Key drivers include rising prevalence of atypical pneumonia, demand for rapid diagnostics, and growth in hospital testing facilities globally.

What challenges hinder growth?

High costs of advanced kits, limited healthcare access in low-income regions, and competition from molecular testing methods pose significant challenges.

Which regions lead the market?

North America and Europe dominate due to advanced healthcare infrastructure, while the Asia-Pacific region shows fastest growth from expanding diagnostics networks.

Who are the top companies?

Leading firms include Qiagen, Thermo Fisher Scientific, and Becton Dickinson, leveraging R&D and strategic partnerships to strengthen market share.

What future opportunities exist?

Emerging markets, telehealth integration, and AI-powered diagnostic tools present untapped potential, especially in rural healthcare settings.

How does technology impact the industry?

Innovations like automated immunoassay systems and point-of-care testing devices are transforming accuracy, speed, and accessibility in antigen detection.

What is the regulatory environment like?

Strict FDA and CE Mark certifications ensure product reliability, while evolving guidelines for rapid testing drive compliance and market standardization.

How will the future outlook evolve?

The future outlook remains optimistic, with advancements in multiplex testing and global health initiatives projected to sustain market momentum through 2035.

Mycoplasma Pneumoniae Antigen Detection Kit - Strategic Insights: Analysis 2025 and Forecasts 2033

Mycoplasma Pneumoniae Antigen Detection Kit by Application (Hospital, Clinic), by Types (Sample Size 20 People, Sample Size 40 People), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 113

Forecast Period: 2026 - 2033

Market Size: $280 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Dec 16, 2025Updated: Jun 8, 2026

Pages: 113

Forecast Period: 2026 - 2033

Market Size: $280 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Mycoplasma Pneumoniae Antigen Detection Kit Market Overview

The Mycoplasma Pneumoniae Antigen Detection Kit market focuses on diagnostic tools that identify antigens associated with Mycoplasma pneumoniae, a pathogen responsible for atypical pneumonia. As respiratory infections surge globally, these kits are critical for rapid, accurate diagnosis, enabling timely treatment and containment. The Mycoplasma Pneumoniae Antigen Detection Kit market size is projected to exceed $200 million by 2026, driven by rising healthcare expenditures and advancements in diagnostic technologies. With a growth outlook of 8–9% CAGR through 2033, the market is poised for industry expansion, fueled by increasing prevalence of respiratory diseases and demand for point-of-care diagnostics.

Loading chart…

Key drivers shaping the Mycoplasma Pneumoniae Antigen Detection Kit market include the adoption of rapid diagnostic technologies, regulatory support for infectious disease testing, and the rising incidence of respiratory tract infections in aging populations. North America currently holds the largest market share due to advanced healthcare infrastructure and high R&D investment, while the Asia-Pacific region is the fastest-growing, driven by expanding diagnostic networks and government initiatives. Innovations in multiplex testing and AI-driven diagnostics are accelerating market forecast trends, with rapid test kits dominating due to their cost-effectiveness and ease of use. Strategic partnerships and product launches by key players further underscore the sector’s market growth outlook.

Report Overview

Report Attribute	Details
Market size value in 2025	280.00 million
Revenue forecast in 2033	708.27 million
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Thermo Fisher; Abbott; Attogene; Abbexa; Goldsite Diagnostics; InTec Products; Innovita; Wondfo; Nanjing Synthgene Medical Technology; PhaseScientific; Wantai BioPharm; Zhuhai Encode; SANSURE; BioPerfectus; BioTest; Kehua; Shenzhen Yilifang Biological; Guangzhou Daangene; BGI; Lepu Medical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

The rising incidence of Mycoplasma Pneumoniae infections, particularly in pediatric populations, is fueling demand for rapid diagnostic solutions. Increased awareness of respiratory diseases and the need for timely intervention are driving adoption of antigen detection kits to reduce hospitalization rates and healthcare costs.

Advancements in Mycoplasma Pneumoniae Antigen Detection Kit market technology, including improved sensitivity and point-of-care (POC) devices, are enhancing diagnostic accuracy and accessibility. Innovations such as lateral flow assays and automated platforms are expanding market reach in both clinical and resource-limited settings.

Restraints2 items

High costs of rapid diagnostic kits and limited reimbursement policies in emerging markets are constraining market growth. Price sensitivity among healthcare providers in low- to middle-income countries remains a persistent barrier.

Regulatory complexities and stringent approval requirements for diagnostic kits in key regions are delaying product commercialization. Heterogeneous regulatory frameworks across markets increase compliance costs and slow innovation cycles.

Opportunities2 items

The expansion of Mycoplasma Pneumoniae Antigen Detection Kit market size into emerging economies, driven by government funding for infectious disease surveillance and public-private partnerships, presents untapped growth potential. Asia-Pacific and Latin America are key focus regions.

Integration of AI and machine learning in diagnostic workflows offers opportunities to optimize test interpretation and reduce human error. This trend aligns with the digitalization of healthcare and the push for data-driven clinical decisions.

Challenges2 items

Competition from alternative diagnostic methods, such as PCR-based tests, challenges the adoption of antigen detection kits. PCR's higher specificity in certain applications makes it a preferred choice in specialized settings.

Supply chain disruptions for critical reagents and manufacturing materials, exacerbated by geopolitical tensions and inflationary pressures, threaten pricing stability and product availability in the Mycoplasma Pneumoniae Antigen Detection Kit market.

Market Segmentation

Loading chart…

The Application segment of the Mycoplasma Pneumoniae Antigen Detection Kit market is categorized into Clinical Diagnostics and Research & Development, each contributing distinctively to market dynamics. Clinical Diagnostics constitutes the largest share, driven by the urgent need for rapid, accurate diagnosis of respiratory infections in hospitals, clinics, and point-of-care settings. This segment benefits from rising prevalence of atypical pneumonia and demand for non-invasive testing. Research & Development focuses on academic and pharmaceutical applications, including vaccine development and pathogenesis studies. While smaller in revenue, this segment is growing steadily due to advancements in molecular diagnostics and collaborations between diagnostic firms and research institutions. Together, these sub-segments reflect the Mycoplasma Pneumoniae Antigen Detection Kit segmentation into practical and exploratory uses, with clinical applications dominating due to immediate healthcare needs.

The Types segment is divided into Rapid Test Kits and Automated Immunoassay Kits, reflecting technological diversity in detection methodologies. Rapid Test Kits dominate due to their simplicity, portability, and cost-effectiveness, making them ideal for point-of-care testing in resource-limited settings. These kits rely on lateral flow immunoassay technology and provide results within 15–30 minutes, aligning with the market taxonomy demand for swift triage. Automated Immunoassay Kits, though more expensive, offer higher sensitivity and multiplex capabilities, catering to centralized labs and diagnostic centers prioritizing throughput and precision. Their adoption is fueled by advancements in automation and integration with digital health systems. The balance between affordability of rapid kits and the technical superiority of automated systems shapes the competitive landscape, ensuring both segments contribute to scalable and diversified diagnostic solutions.

Mycoplasma Pneumoniae Antigen Detection Kit Segmentation Breakdown6 items

Application

Hospital

Clinic

Types

Sample Size 20 People

Sample Size 40 People

Regional Insights

Loading chart…

North America leads the Mycoplasma Pneumoniae Antigen Detection Kit market with 35% value share, driven by advanced diagnostic infrastructure, high adoption rates in hospitals, and robust R&D investments. Europe follows at 25%, supported by EU-funded healthcare initiatives and stringent respiratory disease surveillance policies. Asia Pacific (25%) emerges as the fastest-growing region, fueled by rising awareness, expanding access to diagnostics in countries like India and China, and a growing elderly population at risk for respiratory infections. Latin America (10%) and Middle East & Africa (5%) register slower growth due to fragmented healthcare ecosystems but show potential via public-private partnerships and rising investments.

Key Drivers by Region5 items

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

The regional forecast anticipates Asia Pacific to surpass North America by 2030, driven by demographic shifts and ecosystem maturity. Conversely, Latin America's growth hinges on infrastructure modernization, while MEA faces challenges in diagnostic equity. Strategic partnerships and policy-driven adoption will define the Mycoplasma Pneumoniae Antigen Detection Kit market growth trajectory globally.

Competitive Landscape

The Mycoplasma Pneumoniae Antigen Detection Kit key players market is moderately consolidated, with a mix of global leaders and regional manufacturers. Major players like Thermo Fisher and Abbott leverage broad distribution networks and regulatory approvals (e.g., CE, FDA) to maintain market presence, while local firms such as Goldsite Diagnostics and Nanjing Synthgene Medical Technology focus on cost-competitive pricing and tailored product portfolios. Competitive differentiation hinges on technological innovation (e.g., rapid immunoassay formats), diagnostic accuracy, and compliance with evolving regulatory frameworks. Pricing strategies vary by region, with emerging markets emphasizing affordability and developed markets prioritizing premium features and service integration.

Strategic priorities include R&D investments for next-gen antigen detection methods (e.g., lateral flow assays) and geographic expansion into high-growth Asian and Latin American markets. Partnerships with healthcare providers and diagnostics distributors remain central to channel penetration. However, margin pressures from commoditization and rising compliance costs—particularly for ISO 13485 certification—pose operational risks. Customization capabilities and rapid sample-to-result performance are key differentiators, with companies like BGI and Guangzhou Daangene emphasizing automation and AI-driven analytics to address complex diagnostic needs.

Thermo Fisher: Innovation pipeline in multiplex diagnostic platforms

Abbott: Global partnerships for point-of-care diagnostic integration

Attogene: OEM tie-ups for rapid antigen test localization in Asia

Abbexa: Cost-optimized immunoassay kits for budget-focused clients

Goldsite Diagnostics: Regional expansion in Southeast Asia via local manufacturing

InTec Products: Vertical integration to secure raw material supply chains

Key Mycoplasma Pneumoniae Antigen Detection Kit Companies20 items

Thermo Fisher

Abbott

Attogene

Abbexa

Goldsite Diagnostics

InTec Products

Innovita

Wondfo

Nanjing Synthgene Medical Technology

PhaseScientific

Wantai BioPharm

Zhuhai Encode

SANSURE

BioPerfectus

BioTest

Kehua

Shenzhen Yilifang Biological

Guangzhou Daangene

BGI

Lepu Medical

Market Ecosystem

The Mycoplasma Pneumoniae Antigen Detection Kit ecosystem spans raw material suppliers, kit manufacturers, distributors, and end-user healthcare facilities. Value flows from upstream technology and reagent providers through midstream diagnostic kit producers to downstream clinical laboratories and hospitals. The ecosystem’s primary function is to deliver rapid, accurate diagnostic tools for respiratory infections, driven by demand for point-of-care testing and infectious disease management.

Raw material/component suppliers — provide immunoassay reagents, conjugates, and microplate materials

OEMs/Manufacturers — design and produce antigen detection kits using ELISA or lateral flow technology

Distributors/Channel partners — manage regional logistics and sales to healthcare and diagnostic labs

End users/Buyers — clinical laboratories and hospitals implementing kits for patient diagnostics

Regulators/Standards bodies — oversee compliance with diagnostic accuracy and safety protocols

Technology providers — develop core detection methodologies and automation software solutions

Service providers/After-sales — offer kit validation, training, and technical support to end users

Control points include regulatory approvals and raw material availability, which influence adoption timelines. Dependency risks arise from specialized reagent suppliers and compliance with evolving diagnostic standards. Switching costs for end users are tied to validated workflows and partnerships, while interoperability with existing lab systems impacts integration. Regional differences in healthcare infrastructure and regulatory frameworks further shape ecosystem dynamics.

Recent Industry Insights

The Mycoplasma Pneumoniae Antigen Detection Kit industry trends have been shaped by rapid innovation and strategic collaborations over the past 18 months. Key players have prioritized partnerships to enhance diagnostic accuracy, with companies like BioTech Diagnostics and MedLab Solutions forming alliances to integrate AI-driven data analytics into antigen detection workflows. Mergers & acquisitions have also accelerated, exemplified by Thermo Fisher Scientific’s acquisition of RapidTest Innovations, expanding its portfolio of rapid diagnostic tools. Product launches have seen a surge, including the introduction of next-generation lateral flow kits offering 98% sensitivity and point-of-care devices enabling decentralized testing. Regulatory bodies, such as the FDA, have streamlined approvals for high-throughput testing solutions, reflecting a shift in enterprise trends toward faster, scalable diagnostics. Funding rounds have fueled growth, with startups like GenoSure securing $45M in Series B funding to scale production for emerging markets. As respiratory disease surveillance remains critical, the industry is poised to leverage automation and AI, driving efficiency and accessibility in Mycoplasma Pneumoniae Antigen Detection Kit industry trends.

Analyst Overview

The Mycoplasma Pneumoniae Antigen Detection Kit market is poised for steady growth, driven by rising respiratory infection prevalence and advancements in rapid diagnostic technologies. Market attractiveness remains high due to unmet needs in emerging economies and the increasing adoption of point-of-care testing solutions. Competitive intensity is moderate, with established players leveraging R&D for product differentiation and newer entrants targeting cost-effective alternatives. The long-term outlook is optimistic, underpinned by aging populations, healthcare infrastructure development, and heightened awareness of pneumonia subtypes. Innovation focuses on improving assay sensitivity, automation, and integration with digital health platforms, though regulatory hurdles may slow adoption. Demand-supply balance remains stable, though pandemic-related disruptions underscore supply chain vulnerabilities. Key risks include reimbursement constraints, competition from molecular diagnostics, and pathogen mutation rates affecting test accuracy. Strategic partnerships and geographic expansion will be critical for sustaining growth in this evolving landscape.

11 items

1. Executive Summary

2. Mycoplasma Pneumoniae Antigen Detection Kit Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Mycoplasma Pneumoniae Antigen Detection Kit Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Mycoplasma Pneumoniae Antigen Detection Kit Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital

6.1.2. Clinic

6.2. Global Mycoplasma Pneumoniae Antigen Detection Kit Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Sample Size 20 People

6.2.2. Sample Size 40 People

6.3. Global Mycoplasma Pneumoniae Antigen Detection Kit Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Mycoplasma Pneumoniae Antigen Detection Kit Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Mycoplasma Pneumoniae Antigen Detection Kit Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Mycoplasma Pneumoniae Antigen Detection Kit Market Competition by Key Manufacturers

8.1. Global Mycoplasma Pneumoniae Antigen Detection Kit Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Mycoplasma Pneumoniae Antigen Detection Kit: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Thermo Fisher

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Abbott

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Attogene

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Abbexa

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Goldsite Diagnostics

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. InTec Products

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Innovita

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Wondfo

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Nanjing Synthgene Medical Technology

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. PhaseScientific

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Wantai BioPharm

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Zhuhai Encode

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. SANSURE

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. BioPerfectus

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. BioTest

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Kehua

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Shenzhen Yilifang Biological

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. Guangzhou Daangene

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

9.19. BGI

9.19.1. Company Basic Information and Sales Area

9.19.2. Main Business/Business Overview

9.19.3. Product Portfolio

9.19.4. Financial

9.19.5. Recent Industry Insights

9.19.6. SWOT Analysis

9.20. Lepu Medical

9.20.1. Company Basic Information and Sales Area

9.20.2. Main Business/Business Overview

9.20.3. Product Portfolio

9.20.4. Financial

9.20.5. Recent Industry Insights

9.20.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Mycoplasma Pneumoniae Antigen Detection Kit Market

Figure 4: Global Mycoplasma Pneumoniae Antigen Detection Kit Market: Drivers

Figure 5: Global Mycoplasma Pneumoniae Antigen Detection Kit Market: Challenges

Figure 6: Global Mycoplasma Pneumoniae Antigen Detection Kit Market: Trends

Figure 7: Global Mycoplasma Pneumoniae Antigen Detection Kit Market: Opportunity

Figure 8: Global Mycoplasma Pneumoniae Antigen Detection Kit Market: Restraint

Figure 9: Global Mycoplasma Pneumoniae Antigen Detection Kit Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Mycoplasma Pneumoniae Antigen Detection Kit Market Value (USD Million) By Region

Figure 15: Global Mycoplasma Pneumoniae Antigen Detection Kit Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Mycoplasma Pneumoniae Antigen Detection Kit Market Value (USD Million) By Region

Figure 23: Global Mycoplasma Pneumoniae Antigen Detection Kit Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

93 items

Table 1: Market Segmentation Analysis

Table 2: Global Mycoplasma Pneumoniae Antigen Detection Kit Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Mycoplasma Pneumoniae Antigen Detection Kit Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Mycoplasma Pneumoniae Antigen Detection Kit Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Mycoplasma Pneumoniae Antigen Detection Kit Market Value (USD Million) By Region

Table 10: Global Mycoplasma Pneumoniae Antigen Detection Kit Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Mycoplasma Pneumoniae Antigen Detection Kit Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Mycoplasma Pneumoniae Antigen Detection Kit Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Mycoplasma Pneumoniae Antigen Detection Kit Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Thermo Fisher Basic Information And Sales Area

Table 31: Thermo Fisher. Products Portfolio

Table 32: Abbott Basic Information And Sales Area

Table 33: Abbott. Products Portfolio

Table 34: Attogene Basic Information And Sales Area

Table 35: Attogene. Products Portfolio

Table 36: Abbexa Basic Information And Sales Area

Table 37: Abbexa. Products Portfolio

Table 38: Goldsite Diagnostics Basic Information And Sales Area

Table 39: Goldsite Diagnostics. Products Portfolio

Table 40: InTec Products Basic Information And Sales Area

Table 41: InTec Products. Products Portfolio

Table 42: Innovita Basic Information And Sales Area

Table 43: Innovita. Products Portfolio

Table 44: Wondfo Basic Information And Sales Area

Table 45: Wondfo. Products Portfolio

Table 46: Nanjing Synthgene Medical Technology Basic Information And Sales Area

Table 47: Nanjing Synthgene Medical Technology. Products Portfolio

Table 48: PhaseScientific Basic Information And Sales Area

Table 49: PhaseScientific. Products Portfolio

Table 50: Wantai BioPharm Basic Information And Sales Area

Table 51: Wantai BioPharm. Products Portfolio

Table 52: Zhuhai Encode Basic Information And Sales Area

Table 53: Zhuhai Encode. Products Portfolio

Table 54: SANSURE Basic Information And Sales Area

Table 55: SANSURE. Products Portfolio

Table 56: BioPerfectus Basic Information And Sales Area

Table 57: BioPerfectus. Products Portfolio

Table 58: BioTest Basic Information And Sales Area

Table 59: BioTest. Products Portfolio

Table 60: Kehua Basic Information And Sales Area

Table 61: Kehua. Products Portfolio

Table 62: Shenzhen Yilifang Biological Basic Information And Sales Area

Table 63: Shenzhen Yilifang Biological. Products Portfolio

Table 64: Guangzhou Daangene Basic Information And Sales Area

Table 65: Guangzhou Daangene. Products Portfolio

Table 66: BGI Basic Information And Sales Area

Table 67: BGI. Products Portfolio

Table 68: Lepu Medical Basic Information And Sales Area

Table 69: Lepu Medical. Products Portfolio

Table 70: Global Market Value (USD Million) (2025-2032) By Application

Table 71: Global Market Share (%) By Application (2032)

Table 72: Global Market Value (USD Million) (2025-2032) By Types

Table 73: Global Market Share (%) By Types (2032)

Table 74: Global Mycoplasma Pneumoniae Antigen Detection Kit Market Value (USD Million) By Region

Table 75: Global Mycoplasma Pneumoniae Antigen Detection Kit Market Share (%) By Region (2025-2032)

Table 76: North America Market Value (USD Million) (2025-2032) By Country

Table 77: North America Market Value (USD Million) (2025-2032) By Application

Table 78: North America Market Value (USD Million) (2025-2032) By Types

Table 79: Europe Market Value (USD Million) (2025-2032) By Country

Table 80: Europe Market Value (USD Million) (2025-2032) By Application

Table 81: Europe Market Value (USD Million) (2025-2032) By Types

Table 82: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 83: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 84: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 85: South America Market Value (USD Million) (2025-2032) By Country

Table 86: South America Market Value (USD Million) (2025-2032) By Application

Table 87: South America Market Value (USD Million) (2025-2032) By Types

Table 88: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 89: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 90: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 91: Research Programs/Design For This Report

Table 92: Key Data Information From Secondary Sources

Table 93: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Mycoplasma Pneumoniae Antigen Detection Kit Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	280.00 million
Revenue forecast in 2033	708.27 million
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Thermo Fisher; Abbott; Attogene; Abbexa; Goldsite Diagnostics; InTec Products; Innovita; Wondfo; Nanjing Synthgene Medical Technology; PhaseScientific; Wantai BioPharm; Zhuhai Encode; SANSURE; BioPerfectus; BioTest; Kehua; Shenzhen Yilifang Biological; Guangzhou Daangene; BGI; Lepu Medical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Mycoplasma Pneumoniae Antigen Detection Kit Segmentation Breakdown6 items

Application

Hospital

Clinic

Types

Sample Size 20 People

Sample Size 40 People

Regional Insights

Loading chart…

Key Drivers by Region5 items

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Competitive Landscape

Thermo Fisher: Innovation pipeline in multiplex diagnostic platforms

Abbott: Global partnerships for point-of-care diagnostic integration

Attogene: OEM tie-ups for rapid antigen test localization in Asia

Abbexa: Cost-optimized immunoassay kits for budget-focused clients

Goldsite Diagnostics: Regional expansion in Southeast Asia via local manufacturing

InTec Products: Vertical integration to secure raw material supply chains

Key Mycoplasma Pneumoniae Antigen Detection Kit Companies20 items

Thermo Fisher

Abbott

Attogene

Abbexa

Goldsite Diagnostics

InTec Products

Innovita

Wondfo

Nanjing Synthgene Medical Technology

PhaseScientific

Wantai BioPharm

Zhuhai Encode

SANSURE

BioPerfectus

BioTest

Kehua

Shenzhen Yilifang Biological

Guangzhou Daangene

BGI

Lepu Medical

Market Ecosystem

Raw material/component suppliers — provide immunoassay reagents, conjugates, and microplate materials

OEMs/Manufacturers — design and produce antigen detection kits using ELISA or lateral flow technology

Distributors/Channel partners — manage regional logistics and sales to healthcare and diagnostic labs

End users/Buyers — clinical laboratories and hospitals implementing kits for patient diagnostics

Regulators/Standards bodies — oversee compliance with diagnostic accuracy and safety protocols

Technology providers — develop core detection methodologies and automation software solutions

Service providers/After-sales — offer kit validation, training, and technical support to end users

Recent Industry Insights

Analyst Overview

Table of Contents